A5043941211- Cancer Immunotherapy and Biomarkers
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- CAR-T cell therapy research
- Gastrointestinal Tumor Research and Treatment
- Genetic factors in colorectal cancer
- Cell death mechanisms and regulation
- Cancer Genomics and Diagnostics
- Ultrasound and Hyperthermia Applications
- RNA Interference and Gene Delivery
- Monoclonal and Polyclonal Antibodies Research
- HER2/EGFR in Cancer Research
- Metastasis and carcinoma case studies
- Barrier Structure and Function Studies
- Immunotherapy and Immune Responses
- Cancer Research and Treatments
- Peptidase Inhibition and Analysis
- Pancreatic and Hepatic Oncology Research
- Colorectal and Anal Carcinomas
- Lung Cancer Treatments and Mutations
- Cancer Cells and Metastasis
- Inflammatory Biomarkers in Disease Prognosis
- Immune Cell Function and Interaction
- Cancer Mechanisms and Therapy
- Cholangiocarcinoma and Gallbladder Cancer Studies
Peking University
2016-2025
Peking University Cancer Hospital
2016-2025
American Society for Gastrointestinal Endoscopy
2020
King University
2020
Peking University First Hospital
2020
Ministry of Education
2020
Jilin University
2007
Abstract Despite success in hematologic malignancies, the treatment landscape of chimeric antigen receptor (CAR) T cell therapy for solid tumors remains limited. Claudin18.2 (CLDN18.2)-redirected CAR cells showed promising efficacy against gastric cancer (GC) a preclinical study. Here we report interim analysis results an ongoing, open-label, single-arm, phase 1 clinical trial CLDN18.2-targeted (CT041) patients with previously treated, CLDN18.2-positive digestive system cancers ( NCT03874897...
Autophagy, a process for degrading intracellular substances to maintain basal metabolic turnover, is known be perturbed in gastric cancer. Programmed cell death-1 (PD-1) with its ligand (PD-L1) are important immune checkpoint proteins and their regulation by autophagy has been reported mouse melanoma human ovarian Here, we explored the interplay between PD1/PD-L1 axis cancer.The expression of PD-L1 cancer cells was detected Western blot flow cytometry analysis. The effect inhibition on...
Abstract Purpose RC48 contains the novel humanized anti-HER2 antibody hertuzumab conjugated to MMAE via a cleavable linker. A phase I study was initiated evaluate toxicity, MTD, PK, and antitumor activity of in patients with HER2-overexpressing locally advanced or metastatic solid carcinomas, particularly gastric cancer. Patients methods This 2-part study. Successive cohorts received escalating doses (0.1 mg/kg, 0.5 1.0 2.0 2.5 3.0 mg/kg). Dose expansion proceeded at dose mg/kg Q2W. The...
Although the antibody-drug conjugates (ADCs) have significantly improved survival outcomes of patients with human epidermal receptor 2 (HER2)-expressing gastric or gastroesophageal junction (G/GEJ) cancer, efficacy ADC used as a single agent is limited. Therefore, it necessary to investigate effective and safe combination regimens. Preclinical data indicated synergetic antitumour effect RC48 programmed cell death protein 1 (PD-1) inhibitors. We aimed evaluate safety plus toripalimab in...
Effective interventions to improve prognosis in metastatic esophagogastric cancer (EGC) are urgently needed. We assessed the effect of early integration interdisciplinary supportive care for patients with EGC on overall survival (OS).
Immunotherapy has exhibited promising but controversial results in gastric cancer; determining criteria for choosing the appropriate target population is still problematic. Epstein-Barr virus (EBV)-associated carcinoma (EBVaGC) exhibits distinctive genomic aberrations and clinicopathologic features, positive status of EBV a potential biomarker. We prospectively recruited 9 patients who were diagnosed with stage-IV EBVaGC, all treated by immune-checkpoint inhibitors. The median age was 62...
Abstract Background The FAST study identified claudin-18 (CLDN18.2) as a promising novel therapeutic target for gastric cancer (GC). However, the tumor immune microenvironment and clinicopathological features of CLDN18.2-positive GC are unclear, making it difficult to develop optimize CLDN18.2-targeted treatments. Methods This included 80 patients, 60 whom received anti-PD-1/PD-L1 treatment. CD4/CD8/CD20/CD66b/CD68/CD163/PD-1/PD-L1/TIM-3/LAG-3/FoxP3/CTLA-4/HLA-DR/STING, CLDN18.2 were labeled...
<sec><b>Objective</b>Immunotherapeutic outcomes and clinical characteristics of claudin 18 isoform 2 positive (CLDN18.2-positive) gastric cancer (GC) vary in different studies, making it difficult to optimize anti-CLDN18.2 therapy. We conducted a retrospective analysis explore the association CLDN18.2 expression with clinicopathological immunotherapeutic GC.</sec><sec><b>Methods</b>A total 536 advanced GC patients from 2019 2021 CT041-CG4006 CT041-ST-01 trials were included analysis. on ≥40%...
<sup>68</sup>Ga-labeled nanobody (<sup>68</sup>Ga-NC-BCH) is a single-domain antibody–based PET imaging agent. We conducted first-in-humans study of <sup>68</sup>Ga-NC-BCH for to determine its in vivo biodistribution, metabolism, radiation dosimetry, safety, and potential quantifying claudin-18 isoform 2 (CLDN18.2) expression in gastrointestinal cancer patients. <b>Methods:</b> Initially, we synthesized the probe performed preclinical evaluations on human gastric adenocarcinoma cell...
Immune checkpoint inhibitors (ICIs) have revolutionized the therapeutic landscape of gastrointestinal cancer. However, biomarkers correlated with efficacy ICIs in cancer are still lacking. In this study, we performed 395-plex immune oncology (IO)-related gene target sequencing tumor samples from 96 patients metastatic treated ICIs, and a linear support vector machine learning strategy was applied to construct predictive model. ResultsAll were randomly assigned into discovery (n=72)...
Optimal prognostic biomarkers for patients with gastric cancer who received immune checkpoint inhibitor (ICI) are lacking. Inflammatory markers including lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte (PLR), and systemic inflammation index (SII) easily available. However, its correlation ICI is unknown in cancer. Here, we evaluated the potential association between LMR, PLR, SII clinical outcomes undergoing therapy.We examined at baseline, 6 (± 2) weeks later 139 therapy August...
Immune checkpoint inhibitors (ICIs) have dramatically improved survival in advanced gastrointestinal (GI) cancer patients, but also resulted immune-related adverse events (irAEs). This study aimed to evaluate serological biomarkers of irAEs and treatment response GI patients.Metastatic patients were enrolled between August 1, 2015, July 31, 2017. Serum samples collected at baseline, a panel 59 serum was tested. The occurrence analyzed, biomarker expression correlated with irAE incidence...
Background Gastrointestinal (GI) cancer is the second most common type with mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) phenotype that expected to respond immune-checkpoint inhibitors (ICIs). However, approximately half of patients dMMR/MSI-H GI derive no benefit from ICIs. We sought identify predictors primary resistance ICIs in cancer. Methods Three independent cohorts were included: (1) discovery cohort (65 cancer) ICI efficacy data and pre-ICIs tissue samples...
2501 Background: Autologous anti-claudin18.2 (CLDN18.2) CAR T cell, satricabtagene autoleucel (satri-cel)/CT041, was investigated in gastrointestinal cancers clinical trials. The interim results of CT041-CG4006 trial (NCT03874897) were published June 2022 [1] . Herein, we present the final this trial. Methods: This single-arm, open-label, phase 1 evaluated safety and efficacy CT041 patients (pts) with CLDN18.2-positive advanced (GI) cancers. consisted a dose-escalation (250×10 6 , 375×10...
Chimeric antigen receptor T cell (CAR T) therapy has been successfully used to treat hematological malignancies. Nonetheless, its application solid tumors remains challenging. Our previous analysis of the ongoing clinical trial (NCT03874897) demonstrated promising results in patients with advanced CLDN18.2-positive gastric cancer who received CT041 CAR treatment. Here, we collected peripheral blood and ascites from five 3 7 days (d) after infusion. Patients a high proportion naïve-like cells...
Larotrectinib is the first-in-class, highly selective TRK inhibitor with demonstrated efficacy in various fusion solid tumours. We report and safety of larotrectinib patients gastrointestinal (GI) cancer. Patients GI cancer from NAVIGATE (NCT02576431) were included. Response was independent review committee (IRC)-assessed per RECIST v1.1. As July 2023, 44 enrolled. Tumour types included colorectal (CRC; n = 26), pancreatic (n 7), cholangiocarcinoma 4), gastric 3), one each appendiceal,...
To evaluate the efficacy and safety of KN026, a novel bispecific HER2 (ECD2 ECD4) antibody, plus KN046, PD-L1, CTLA4 in patients with advanced HER2-positive solid tumors. We conducted two sequentially designed phase Ib II studies similar target populations evaluation schedules. The primary endpoints included safety, maximum tolerated dose (MTD), recommended (RP2D) for study, objective response rate (ORR) duration (DoR) study. Hereby, we solely report results from 113 nonbreast cancer...